Lung Cancer

This video examines a phase II trial that studied maintenance pembrolizumab in extensive-stage small-cell lung cancer.

Dacomitinib delayed progression of EGFR-positive non–small-cell lung cancer, but led to more adverse events compared with gefitinib.

The FDA has expanded the approval for ceritinib. The agent is now approved as a first-line treatment in patients with metastatic, ALK-positive, non-small-cell lung cancer.

Ahead of the 2017 ASCO Annual Meeting, we discuss how to approach treatment for older patients with lung cancer.

This video reviews options for radiation therapy in the treatment of small-cell lung cancer, including dosing frequency and use of thoracic and cranial irradiation in extensive-stage disease.

This video examines the role of radiation therapy in early-stage lung cancer and some of the data comparing stereotactic ablative radiotherapy vs surgery in these patients.

A new study has found that high tumor mutation load is associated with older age, absence of oncogenic mutations, and presence of tumor suppressor gene mutations.

Evidence suggests that the inclusion of ventilation in cigarette filters has contributed to the increased rate of lung adenocarcinoma among smokers.

Higher doses of the kinase inhibitor brigatinib as second-line therapy for ALK-positive non–small-cell lung cancer may be an option for some patients.

Adjuvant gefitinib significantly prolonged time to recurrence compared with the standard of care for patients with NSCLC with EGFR-activating mutations.

The FDA has approval pembrolizumab (Keytruda), in combination with chemotherapy, for the first-line treatment of patients with metastatic non-squamous non–small-cell lung cancer.

Seasonal influenza vaccination resulted in increased risk of immune-related adverse events in lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors, though risk of the flu itself may still outweigh the risks associated with vaccination.

This video examines how the use of radiation therapy in patients on immunotherapy can trigger immunogenic cell death, and reviews some of the challenges related to unwanted immune responses from radiotherapy.

Adding selumetinib to docetaxel does not provide any significant benefit over docetaxel alone for patients previously treated for advanced KRAS-mutant non–small-cell lung cancer.

Pretreatment with immune checkpoint inhibitors are associated with a higher likelihood of response to salvage chemotherapy in patients with advanced non–small-cell lung cancer.

This video reviews immunotherapy trials in small-cell lung cancer, including studies on pembrolizumab, nivolumab monotherapy, and nivolumab in combination with ipilimumab.

Researchers report that an analysis of ALK copy number in circulating tumor cells before starting crizotinib treatment and after 2 months of crizotinib treatment may provide a biomarker for predicting the effectiveness of the drug.

The FDA has approved brigatinib (Alunbrig) for the treatment of metastatic ALK-positive non-small-cell lung cancer, specifically in patients who have progressed on or are intolerant to crizotinib.

Peripheral blood analysis may provide valuable insights into non–small-cell lung cancer patients’ responses to PD-1-targeted therapies.

Circulating tumor DNA blood tests can rapidly identify treatment-targetable tumor mutations in patients diagnosed with non–small-cell lung cancer.

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy regimens failed to prolong overall survival in lung and breast cancers.

Dr. Heather Wakelee discusses the management of lung cancer patients who have early or delayed progression while being treated with an immune checkpoint inhibitor.

We spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.

We spoke with Dr. Julie Brahmer about how survival rates are starting to improve with the use of nivolumab in non-small cell lung cancer.

In this video we discuss a new study that tested the feasibility of using circulating tumor cells to detect recurrence in patients with locally advanced non–small-cell lung cancer.